Details for Patent: 6,770,304
✉ Email this page to a colleague
Title: | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Abstract: | The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations. |
Inventor(s): | Warrell, Jr.; Raymond P. (Westfield, NJ), Pandolfi; Pier Paolo (New York, NY), Gabrilove; Janice L. (New York, NY) |
Assignee: | Memorial Sloan-Kettering Cancer Center (New York, NY) |
Filing Date: | Nov 10, 1998 |
Application Number: | 09/189,965 |
Claims: | 1. A method of treating acute myelogenous leukemia in a human comprising administering to a human having acute myelogenous leukemia a therapeutically effective amount of arsenic trioxide, wherein the acute myelogenous leukemia is selected from the group consisting of acute myeloblastic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, or acute undifferentiated leukemia. 2. A method for treating chronic myelogenous leukemia in a human comprising administering to a human with chronic myelogenous leukemia a therapeutically effective amount of arsenic trioxide. 3. A method for treating acute myelogenous leukemia or chronic myelogenous leukemia in a human who is resistant to treatment with retinoids comprising administering to the human a therapeutically effective amount of arsenic trioxide, wherein the acute myelogenous leukemia is selected from the group consisting of acute myeloblastic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, or acute undifferentiated leukemia. 4. The method of claim 1, 2, or 3, wherein arsenic trioxide is administered by intravenous infusion. 5. The method of claim 4 wherein about 1 to 40 mg of arsenic trioxide is administered per day. 6. The method of claim 1, 2, or 3, wherein administration of arsenic trioxide is repeated daily until bone marrow remission is observed in the human. 7. The method of claim 1, 2, or 3, wherein all-trans retinoic acid is also administered to the human. |